Shalaby Tamer, Anandappa Samantha, Sivappriyan Siva, Kumar Jesse
Registrar in Acute Medicine and Endocrinology.
CT1 Endocrinology.
Eur Endocrinol. 2014 Aug;10(2):151-152. doi: 10.17925/EE.2014.10.02.151. Epub 2014 Aug 28.
Denosumab is a monoclonal antibody which is currently licensed in the UK drug market for the prevention of skeletal-related events secondary to malignancy (excluding myeloma). This monoclonal antibody is a 6 monthly subcutaneous injection that works by lowering calcium levels. When used in a 90 year old patient with primary hyperparathyroidism it demonstrated a dramatic reduction in the calcium level which had proven difficult to reduce by bisphosphonates and who was not a candidate for surgical intervention.
地诺单抗是一种单克隆抗体，目前在英国药品市场上被批准用于预防继发于恶性肿瘤（不包括骨髓瘤）的骨相关事件。这种单克隆抗体每6个月皮下注射一次，通过降低钙水平发挥作用。在一名90岁的原发性甲状旁腺功能亢进患者中使用时，它使钙水平显著降低，而双膦酸盐类药物此前难以降低该患者的钙水平，且该患者不适合进行手术干预。
